Intidhar Labidi-Galy
Overview
Explore the profile of Intidhar Labidi-Galy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, et al.
Nat Commun
. 2024 Jul;
15(1):5932.
PMID: 39013886
PD-1/PD-L1 blockade has so far shown limited survival benefit for high-grade ovarian carcinomas. By using paired samples from the NeoPembrOv randomized phase II trial (NCT03275506), for which primary outcomes are...
2.
Dibitetto D, Liptay M, Vivalda F, Dogan H, Gogola E, Gonzalez Fernandez M, et al.
Nat Commun
. 2024 May;
15(1):4430.
PMID: 38789420
Histone H2AX plays a key role in DNA damage signalling in the surrounding regions of DNA double-strand breaks (DSBs). In response to DNA damage, H2AX becomes phosphorylated on serine residue...
3.
Balmana J, Fasching P, Couch F, Delaloge S, Labidi-Galy I, OShaughnessy J, et al.
Breast Cancer Res Treat
. 2023 Dec;
204(2):237-248.
PMID: 38112922
Purpose: The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic...
4.
Zielli T, Labidi-Galy I, Del Grande M, Sessa C, Colombo I
Cancer Drug Resist
. 2023 Oct;
6(3):499-516.
PMID: 37842243
Ovarian cancer is the most lethal gynecologic cancer. Optimal cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab is the conventional therapeutic strategy. Since 2016, the pharmacological treatment of...
5.
Borgeaud M, Courtes M, Tsantoulis P, Bodmer A, Labidi-Galy I, Koessler T
Praxis (Bern 1994)
. 2023 Mar;
112(3):149-155.
PMID: 36855887
Immunotherapy is becoming increasingly important in the management of urological, gynecological, and gastrointestinal cancers. Immune checkpoint inhibitor-based combinations have become a standard of care for patients with metastatic renal and...
6.
Lang N, Diciola A, Labidi-Galy I, Ris F, Di Marco M, Mach N, et al.
BMJ Open
. 2023 Jan;
13(1):e067691.
PMID: 36604127
Introduction: Intraperitoneal dissemination is a major problem resulting in very poor prognosis and a rapid marked deterioration in the quality of life of patients. Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is...
7.
Undurraga M, Mathevet P, Hubner M, Buchs N, Warlaumont M, Sarivalasis A, et al.
Rev Med Suisse
. 2022 May;
18(782):990-996.
PMID: 35583278
Ovarian cancer is the first cause of death by gynecological cancer. Most of the patients are diagnosed with peritoneal carcinomatosis that represents a therapeutic challenge. Its management implies maximal cytoreductive...
8.
Bordry N, Addeo A, Jaksic C, Dutoit V, Roux-Lombard P, Shah D, et al.
iScience
. 2022 Jan;
25(1):103699.
PMID: 34977496
Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2...
9.
Addeo A, Shah P, Bordry N, Hudson R, Albracht B, Di Marco M, et al.
Cancer Cell
. 2021 Jul;
39(8):1091-1098.e2.
PMID: 34214473
Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however,...
10.
Gelmon K, Fasching P, Couch F, Balmana J, Delaloge S, Labidi-Galy I, et al.
Eur J Cancer
. 2021 Jun;
152:68-77.
PMID: 34087573
Background: In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2...